Provided by Tiger Trade Technology Pte. Ltd.

Enveric Biosciences

2.00
-0.1100-5.21%
Volume:29.93K
Turnover:61.16K
Market Cap:2.78M
PE:-0.02
High:2.16
Open:2.13
Low:1.96
Close:2.11
52wk High:54.00
52wk Low:1.96
Shares:1.39M
Float Shares:1.28M
Volume Ratio:0.63
T/O Rate:2.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-93.5500
EPS(LYR):-228.4745
ROE:-262.78%
ROA:-133.22%
PB:0.80
PE(LYR):-0.01

Loading ...

Company Profile

Company Name:
Enveric Biosciences
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
6
Office Location:
245 First Street,Riverview II,18 th Floor,Cambridge,Massachusetts,United States
Zip Code:
02142
Phone:
- -
Fax:
- -
Introduction:
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Directors

Name
Position
Joseph Tucker
Chief Executive Officer and Director
Michael D. Webb
Chairman of the Board and Independent Director
Frank Pasqualone
Independent Director
George Kegler
Independent Director
Marcus Schabacker
Independent Director
Sheila DeWitt
Director

Shareholders

Name
Position
Joseph Tucker
Chief Executive Officer and Director
Kevin Coveney
Chief Financial Officer
Peter Facchini
Chief Innovation Officer